Clinical outcomes at 12 to 24 months of hip arthroscopy versus personalized hip therapy in patients with femoroacetabular impingement: a systematic review and meta-analysis

Purpose To systematically evaluate and compare 12 to 24 months between hip arthroscopy (AHS) and personalized hip therapy (PHT) in patients with femoroacetabular impingement syndrome(FAIS), and to provide evidence-based guidance for clinical decision-making. Methods This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines and prospectively registered in PROSPERO (CRD420251066546). PubMed, Cochrane Library, and other databases were searched from June 2015 to June 2025. Five randomized controlled trials (846 patients) were included. Outcomes included patient-reported measures (iHOT-33, HOS-ADL, HOS-sports, EQ-5D index, EQ-5D VAS) and radiological parameters (maximum alpha angle, lateral center–edge angle). A random-effects model was applied for meta-analysis; narrative synthesis was employed for outcomes with insufficient data. Results AHS demonstrated significantly superior functional outcomes at 12-month follow-up: iHOT-33 (WMD 14.47, 95% CI 7.45–21.50, I 2 =81%), HOS-ADL (WMD 12.40, 95% CI 8.56–16.24, I 2 =31%), and HOS-sports (WMD 13.62, 95% CI 7.73–19.52, I 2 =48%), with all advantages persisting at 24 months. Health-related quality of life measures also significantly favored AHS at 12 months: EQ-5D index (WMD 0.08, 95% CI 0.01–0.14, I 2 =84%) and EQ-5D VAS (WMD 4.36, 95% CI 0.91–7.82, I 2 =52%). AHS significantly reduced the maximum alpha angle by 8.26° (95% CI −10.71 to −5.81, I 2 =0%) at 12 months. Conclusions AHS showed consistently better outcomes than PHT across hip-specific function, quality of life, and radiological measures at 12 to 24 months. Certainty of evidence was high for the alpha angle, moderate for iHOT-33 at 24 months and HOS-ADL at 12 months, and low to very low for the remaining outcomes. These findings support AHS as an effective treatment for FAIS, though individual patient circumstances should still guide clinical decisions.

Authors

Institutions

Publication Details

Journal
Journal of Orthopaedic Surgery and Research
Published
2026-11-21
DOI
https://doi.org/10.1186/s13018-026-07260-x
Primary Topic
Hip disorders and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical outcomes at 12 to 24 months of hip arthroscopy versus personalized hip therapy in patients with femoroacetabular impingement: a systematic review and meta-analysis

Xinyang Huang, Zhe Xue, Hao-xuan Li, Zi-hao Deng et al.
Journal of Orthopaedic Surgery and Research
Hip disorders and treatments
article

Clinical outcomes at 12 to 24 months of hip arthroscopy versus personalized hip therapy in patients with femoroacetabular impingement: a systematic review and meta-analysis

Xinyang Huang, Zhe Xue, Hao-xuan Li, Zi-hao Deng, Jin Zhang
article en

Abstract

Purpose To systematically evaluate and compare 12 to 24 months between hip arthroscopy (AHS) and personalized hip therapy (PHT) in patients with femoroacetabular impingement syndrome(FAIS), and to provide evidence-based guidance for clinical decision-making. Methods This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines and prospectively registered in PROSPERO (CRD420251066546). PubMed, Cochrane Library, and other databases were searched from June 2015 to June 2025. Five randomized controlled trials (846 patients) were included. Outcomes included patient-reported measures (iHOT-33, HOS-ADL, HOS-sports, EQ-5D index, EQ-5D VAS) and radiological parameters (maximum alpha angle, lateral center–edge angle). A random-effects model was applied for meta-analysis; narrative synthesis was employed for outcomes with insufficient data. Results AHS demonstrated significantly superior functional outcomes at 12-month follow-up: iHOT-33 (WMD 14.47, 95% CI 7.45–21.50, I 2 =81%), HOS-ADL (WMD 12.40, 95% CI 8.56–16.24, I 2 =31%), and HOS-sports (WMD 13.62, 95% CI 7.73–19.52, I 2 =48%), with all advantages persisting at 24 months. Health-related quality of life measures also significantly favored AHS at 12 months: EQ-5D index (WMD 0.08, 95% CI 0.01–0.14, I 2 =84%) and EQ-5D VAS (WMD 4.36, 95% CI 0.91–7.82, I 2 =52%). AHS significantly reduced the maximum alpha angle by 8.26° (95% CI −10.71 to −5.81, I 2 =0%) at 12 months. Conclusions AHS showed consistently better outcomes than PHT across hip-specific function, quality of life, and radiological measures at 12 to 24 months. Certainty of evidence was high for the alpha angle, moderate for iHOT-33 at 24 months and HOS-ADL at 12 months, and low to very low for the remaining outcomes. These findings support AHS as an effective treatment for FAIS, though individual patient circumstances should still guide clinical decisions.

Journal of Orthopaedic Surgery and Research
Capital Medical University (CN), Peking University (CN), Beijing Jishuitan Hospital (CN), Beijing YouAn Hospital (CN), Beijing Shijitan Hospital (CN)
Hip disorders and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon